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Abstract
Sirtuin deacetylases regulate diverse cellular pathways and influence disease processes.
Our previous studies identified the brain-enriched sirtuin-2 (SIRT2) deacetylase as a poten-
tial drug target to counteract neurodegeneration. In the present study, we characterize
SIRT2 inhibition activity of the brain-permeable compound AK7 and examine the efficacy of
this small molecule in models of Parkinson’s disease, amyotrophic lateral sclerosis and ce-
rebral ischemia. Our results demonstrate that AK7 is neuroprotective in models of Parkin-
son’s disease; it ameliorates alpha-synuclein toxicity in vitro and prevents 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopamine depletion and dopaminergic
neuron loss in vivo. The compound does not show beneficial effects in mouse models of
amyotrophic lateral sclerosis and cerebral ischemia. These findings underscore the speci-
ficity of protective effects observed here in models of Parkinson’s disease, and previously in
Huntington’s disease, and support the development of SIRT2 inhibitors as potential thera-
peutics for the two neurodegenerative diseases.
Introduction
Mammalian NAD+-dependent sirtuin deacetylases (SIRT1-SIRT7) regulate diverse physiologi-
cal functions in cells and are implicated as potential modifiers of neurogenerative diseases [1].
The second family member, SIRT2, has been identified as an α-tubulin deacetylase [2]. It has
become evident however, that SIRT2 acts on a broad variety of protein substrates implicated in
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important cellular processes, including transcriptional regulation, cytoskeletal organization,
and microtubule dynamics, suggesting a broad regulatory role for this protein that is likely dis-
tinct in different cell types [3, 4]. SIRT2 is highly abundant in the adult brain, where its alterna-
tively spliced truncated isoform (SIRT2.2) is preferentially expressed and accumulates with age
[5]. High-level of SIRT2 expression is detected in oligodendrocytes [6, 7]. SIRT2 is expressed in
neurons as well, although the precise protein function(s) in these cells is still uncertain [5, 8].
Recently, an intronic polymorphism in the SIRT2 gene (SNP rs10410544) has been identified
as a risk factor and modifier of Alzheimer’s disease, further illuminating the role of this deace-
tylase in neurodegeneration [9, 10].
We previously showed that genetic or pharmacological inhibition of SIRT2 is protective in
primary neuronal and invertebrate animal models of Parkinson’s disease (PD) [11]. Among
the small molecule SIRT2 inhibitors, AK-1, a sulfobenzoic acid derivative, showed consistent
protective effects [11]. In addition, brain delivery of AK-1 by an osmotic minipump was safe
and neuroprotective in a mouse model of frontotemporal dementia (FTD) based on the expres-
sion of mutant tau protein [12]. Protective effects of the AK-1 SIRT2 inhibitor have also been
shown in primary neuronal, C. elegans, and Drosophilamodels of Huntington’s disease (HD)
[8]. Subsequently, we developed a brain-permeable analog of AK-1, the sulfobenzoic acid de-
rivative AK7, and characterized its selective SIRT2 inhibition activity and protective effects in
primary HD neurons [13]. Furthermore, treatment with AK7 improved motor function, ex-
tended survival, and reduced brain atrophy in two genetic mouse models of HD [14]. Overall,
these results suggest that AK7-medicated SIRT2 inhibition counteracts
neurodegenerative processes.
In the present study, we characterized the mechanism of action of the brain-permeable
SIRT2 inhibitor AK7 and examined its efficacy in cellular aSyn and mouse 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) models of PD. aSyn and MPTP represent genetic and envi-
ronmental factors that have been implicated in the etiology of the second most common neuro-
degenerative disease [15, 16]. In addition, to explore potential general benefits of
pharmacological SIRT inhibition in neurological conditions, we also tested efficacy of AK7 in
established mouse models of amyotrophic lateral sclerosis (ALS) and cerebral ischemia.
Roles of SIRT2 have been proposed but remain to be defined in both ALS and cerebral ische-
mia [17–19].
Results
AK7 inhibits SIRT2 and protects against aSyn toxicity in vitro
Our previous data have shown that treatment with AK7 increases lysine 40 (K40) acetylation
of α-tubulin, a well-known substrate of SIRT2, in neuronal cells [13]. To characterize the
mechanism by which brain-permeable AK7 inhibits the activity of the SIRT2 deacetylase, we
conducted dose-response experiments with recombinant human SIRT2 and acetylated K40- α-
tubulin peptide under standard conditions (80 μM peptide/1 mMNAD+), which yielded AK7
IC50 of 33.8 ± 18.4 M (Fig. 1A). Further dose-response experiments were performed in SIRT2
deacetylation reactions with lower NAD+ (200 μM) or higher α-tubulin peptide concentration
(400 μM), yielding IC50 values of 11.4 ± 1.1 μM and 9.8 ± 1.6 μM respectively. The fact that the
IC50 decreased at lower NAD
+ concentrations suggests a competition between AK7 and
NAD+. The behavior with respect to the peptide concentration, however, was less clear. The
IC50 value was significantly decreased from 33.8 ± 18.4 μM to 9.8±1.6 μMwith an increase of
peptide concentration, indicating non-competitive binding, i.e. peptide support for compound
binding. However, the change of IC50 was solely due to an increase of non-inhibited back-
ground activity, from*55% under standard conditions and low NAD+ concentration to
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*90% with high peptide concentration (Fig. 1A), but not due to a sideways shift of the transi-
tion points. We thus assume that the potency was not directly affected by the peptide, i.e. that
SIRT2 inhibition by AK7 is not competitive with the substrate peptide.
Based on the competition results, we generated models for AK7 binding to SIRT2 through
docking calculations with SIRT2-peptide complexes. In all three docking procedures (see Ex-
perimental procedures) the best pose of AK7 mainly occupies the NAD+ binding site of SIRT2
(Fig. 1B; S1A-B Fig.), which is consistent with the NAD+ competitive mechanism of inhibi-
tion. However, slightly varying poses of AK7 were observed. The compound could be observed
in both orientations, and slide to different extents into the binding region for the ADP part of
NAD+. With its terminal ring system, it can either occupy the C-site, which normally
Figure 1. Characterization of the SIRT2 inhibitor AK7 in vitro and in a cell model of aSyn toxicity. (A) Determination of AK7 IC50 on SIRT2 deacetylase
activity at varying substrate (α-tubulin K40 peptide) and co-factor (NAD+) concentrations (circles 80 μM α-tubulin/1 mMNAD+; squares 80 μM α-tubulin/
200 μMNAD+; triangles 400 μM α-tubulin/1 mMNAD+). Each data point is the average of at least 3 independent measurements. IC50 fits are shown as lines.
(B) Docking model of a SIRT2/AK7 complex. The structure of SIRT2 (PDB ID 3zgv) is shown in gold with the catalytic His187. ADP-ribose and substrate
acetylated lysine are shown in light green and deep teal, respectively. The best pose of AK7 (magenta) mainly occupies the NAD+ binding site. (C) LUHMES
cells were transduced with a lentivirus encoding aSyn. 10 days after differentiation, in the presence of vehicle alone (red, 100% toxicity) or different
concentrations of AK7 (black line), media were collected and AK activity was measured. (D) Percentage of AK activity in the presence of 12.5 μ of AK7,
compared to vehicle-treated cells (**p<0.01).
doi:10.1371/journal.pone.0116919.g001
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accommodates nicotinamide and has been described as an occupancy site for several other
sirtuin inhibitors [20, 21] (S1A Fig.), or the entry of a large, SIRT2-specific cavity behind the
C-site [22] (S1B Fig.). In an alternative model, the compound occupancy essentially over-
lapped with the ADP-ribose part of NAD+ (S1B Fig.). Any of these positions might explain the
NAD+ competitive mechanism of SIRT2 inhibition by AK7. Considering its selectivity of
SIRT2 inhibition [13], we assume that the compound predominantly exploits the SIRT2-specif-
ic active site cavity (Fig. 1B). The uncertain interaction of the inhibitor with the peptide might
also indicate different AK7 poses in inhibition, depending on the presence of a specific peptide
as substrate for deacetylation.
Next, based on our previous study, we confirmed the protective activity of the SIRT2 inhibi-
tor AK7 against aSyn toxicity [11]. Here, we employed a cellular aSyn model of PD in condi-
tionally-immortalized, non-transformed human fetal LUHMES cells differentiated to acquire a
dopaminergic neuron-like phenotype under appropriate growth conditions [23, 24]. Overex-
pression of lentivirus-delivered aSyn in LUHMES cells causes cytotoxicity, which result in two-
fold higher release of adenylate kinase (AK) into the culture media, a readout of membrane in-
tegrity and cytotoxicity [11]. The effects of AK7 on the viability of LUHMES cells overexpres-
sing aSyn were assessed in a dose-dependent manner (Fig. 1C). Dose-dependent protective
effects of AK7 were observed, and maximal protection was reached at 12.5 μM (Fig. 1C-D).
Similar protective effects was achieved using a structurally distinct SIRT2 inhibitor,
3-(benzylthio)-5-[(1-naphthyloxy)methyl]-4-phenyl-4H-1,2,4-triazole (MIND4-11), are
shown in S1C-D Fig. for comparison.
AK7 protects against MPTP neurotoxicity in mice
We then examined the neuroprotective effects of AK7 in in vivoMPTP model of PD [15, 25]
(Figs. 2 and 3). In the acute MPTP paradigm, in which animals were injected i.p. once with
MPTP 40 mg/kg, and with AK7 at 30 mg/kg 10 min before and 50 min after MPTP injection.
AK7 rescued MPTP-induced loss of dopamine (DA) and of the metabolite dihydroxyphenyla-
cetic acid (DOPAC) in the striatum (Fig. 2A, B). AK7, however, appeared to alter MPTP me-
tabolism in the acute setting. Increased levels of MPP+, the active, toxic metabolite of MPTP,
were detected in the striatum of AK7 treated animals 90 min after MPTP injection (Fig. 2C).
Thus, AK7 might have even stronger neuroprotective effects to overcome neurotoxicity of in-
creased MPP+ in the acute paradigm.
In the subacute paradigm (Fig. 3), AK7, when administrated i.p. at 20 mg/kg 10 min before
and 50min after MPTP 20 mg/kg i.p. once daily for 4 days, improved beam performance 3 days
after the last MPTP injection (Fig. 3A). High performance liquid chromatography (HPLC)
coupled with electrochemical detection (ECD) showed that AK7 at 20 mg/kg attenuated DA
loss induced by MPTP in the striatum (Fig. 3B). Dopaminergic cell counts in the substantia
nigra (SN) demonstrated preservation of dopaminergic neurons in AK7 + MPTP treated mice
compared to mice treated with MPTP alone (Fig. 3C), as illustrated in Fig. 3D showing tyro-
sine hydroxylase (TH) -immunostained dopaminergic neurons in the SN. Significant increase
of α-tubulin aectylation in the striatum after AK7 treatment was displayed by Western Blot-
ting, confirming compound brain bioactivity of SIRT inhibition; the expression of SIRT2 pro-
tein itself (isoform SIRT2.2) was unchanged, as expected (Fig. 3E, F).
Effects of AK7 in a mouse models of ALS
In a parallel study, we evaluated the effects of AK7 on disease onset and survival in a mouse
model of ALS. These studies were conducted using SOD1-G93A transgenic mice (strain B6.
Cg-Tg (SOD1G93A)1Gur/J), which express an ALS-linked human mutant allele of SOD1
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[26] and are the in vivomodel of choice for preclinical efficacy studies in ALS [27, 28]. We ob-
served no significant effect on disease onset or survival in these animals following chronic
treatment with AK7 (Fig. 4). These results are in accord with a recent report that genetic abla-
tion of SIRT2 does not alter disease progression in ALS mice [29].
Effects of AK7 in a mouse model of ischemic stroke
A role for SIRT2 in mediating programmed necrosis, and a possible amelioration of necrotic
injuries, including those that result from ischemic stroke and myocardial infarction, by inhibi-
tion of SIRT2 enzyme activity has been proposed but remains controversial [18, 19]. We exam-
ined the effects of AK7 in an experimental mouse model of cerebral ischemia. We did not
detect a significant difference between vehicle and AK7-treated groups in mortality, infarct vol-
umes, ischemic tissue swelling, or neurological deficit scores (Table 1).
Figure 2. Protective effects of AK7 in acute MPTPmousemodel of PD.Mice received a single injection
(i.p.) of MPTP at 40 mg/kg or saline. AK7 30 mg/kg was injected i.p. 10 min before and 50 min after MPTP
administration. Animals were sacrificed 7 days after the injection. Striatal DA (A) and metabolite DOPAC (B)
were detected by HPLC-ECD (A&B, n = 8–10, *p<0.05 vs CON; # p<0.05 vs MPTP). (C) For determination
of MPTPmetabolism, mice were injected with MPTP and AK7 (10 min before and 50 min after MPTP) at
indicated doses and sacrifice 90 min after MPTP treatment. MPP+ was detected in the striatum by HPLC (C,
n = 5–6, ** ##, p<0.01 vs corresponding MPTP control groups).
doi:10.1371/journal.pone.0116919.g002
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Figure 3. Protective effects of AK7 in subacute MPTPmousemodel of PD.Mice were treated with MPTP i.p. at 20 mg/kg once daily for 4 days and
sacrificed 5 days after the last injection. AK7 was injected at 10 or 20 mg/kg i.p. 10 min before and 50 min after MPTP administration. (A) Beam test was
performed 3 days after the last MPTP administration. (B) Striatal DA was detected by HPLC-ECD. TH immunohistochemistry was performed and nigral
Neuroprotective Effects of the SIRT Inhibitor AK-7
PLOS ONE | DOI:10.1371/journal.pone.0116919 January 21, 2015 6 / 15
Discussion
The present study characterized the SIRT2 inhibition property of the previously identified
small molecule AK7 [17] and its effects in models of three neurodegenerative conditions: PD,
ALS, and ischemic stroke. Our results demonstrated that AK7 is neuroprotective only in mod-
els of PD. Treatment with AK7 protects dopaminergic neurons against aSyn-induced neuro-
toxicity in differentiated LUHMES cells; in MPTP mouse model, systemic administration of
AK7 prevents DA loss, promotes long-term survival of dopaminergic neurons, and preserves
functional performance.
The observation that AK7 is neuroprotective in aSyn overexpressing LUHMES cells is con-
sistent with our previous report [11]. The protective effects of AK7 in MPTP mouse model of
PD are less expected, since this neurotoxin interferes with mitochondrial complex I. AK7
shows high in vitro selectivity for SIRT2, and accordingly increases α-tubulin acetylation (used
here as a pharmacodynamic marker for compound activity in vivo) in the striatum of MPTP
treated mice. It remains to be determined how AK7-mediated SIRT2 inhibition protects
against both the genetic and environmental factors in PD. Most likely the beneficial influence
of SIRT2 inhibition arises from AK7’s effects on multiple downstream targets/pathways, which
are beginning to emerge [4]. The protective actions of AK7 counteracting MPTP toxicity might
also be related to aSyn, as implicated by previous studies [30, 31], which would suggest aSyn as
a point of convergence of SIRT2-mediated protective pathways in the case of PD.
AK7 treatment increases the concentration of MPP+, an active neurotoxic form of MPTP,
in the striatum at the peak time after MPTP systemic administration [25], suggesting that the
protective effects of SIRT2 inhibition could be underestimated in this model. In initial assess-
ment of possible mechanisms of altered MPTP metabolism, we found no evidence that mono-
amine oxidase B (MOA-B) that is responsible for the metabolic conversion of MPTP to MPP+
is a substrate for SIRT2 deacetylase [4]. Despite SIRT2 selectivity of AK7 in vitro, we cannot ex-
clude that the compound may interact with other structurally similar proteins when adminis-
tered in vivo, although whether and how such off-target activity contributes to the altered
MPTP metabolism are utterly unknown.
The small, brain-permeable compound AK7 mediates neuroprotection in neuronal and
mouse models of PD and HD, indicating common underlying mechanisms in different neuro-
degenerative diseases and general benefits of pharmacological SIRT2 inhibition [1]. These data
suggest that SIRT2 inhibition may stimulate broad neuroprotective responses, downstream
from the specific pathological changes that occur in each neurodegenerative condition. Such
protective beneficial responses, for example, could be broadly specific to stimulation of micro-
tubule-dependent trafficking or global transcriptional activity.
However, in contrast to pharmacological treatment, no changes in neurological phenotype
in the fragment HDmouse model R6/2 were evident in SIRT2 KO genetic background [14,
32]. There were no effects of AK7 treatment in the SOD1-G93A mouse model of ALS, consis-
tent with previously reported negative results of SIRT2 genetic knockout in these mice [29]. Al-
though our preclinical efficacy test of AK7 in a mouse model of ALS yielded negative results,
this finding is consistent with the less defined and potentially conflicting roles of SIRT2 in ALS
[17]. Moreover, treatment with AK7 was not beneficial in mouse model of stroke, where a
dopaminergic neurons were counted by stereological analysis of TH positive neurons (C and D). A separate experiment was performed using the same
treatment regimen but mice were sacrificed 24 hr after the last MPTP injection. Acetylated α-tubulin (Ac-tubulin), total α-tubulin, and brain-predominant
SIRT2.2 isofrom was detected in the striatum byWestern Blotting (E) and the blot was quantified using Image J (F). (*p<0.05 vs CON; # p<0.05 vs MPTP;
** p<0.01 vs MPTP).
doi:10.1371/journal.pone.0116919.g003
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therapeutic role of SIRT2 inhibition has been proposed but remains controversial [18, 19].
These negative results suggest specificity of the neuroprotective effects mediated by AK7 in
Parkinson’s and Huntington’s disease models and underscore the significance of these effects
as observed in this and previous studies [14].
Figure 4. Effects of AK7 in SOD1-G93Amousemodel of ALS. Kaplan-Meier probability curves show no significant effects of AK7 treatment on (A)
symptom onset (118 ± 10.0 days for AK7, 117 ± 8.6 days for vehicle-treated controls) or (B) survival (169 ± 12.7 days for AK7, 175 ± 12.4 days for controls) of
SOD1-G93A mice in this study. Values are median age ± SD; n = 23 for AK7, n = 27 for vehicle-treated controls.
doi:10.1371/journal.pone.0116919.g004
Neuroprotective Effects of the SIRT Inhibitor AK-7
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In light of previous studies, the present investigation confirms a critical role for the SIRT2
pathway in PD pathophysiology, where the benefits of SIRT2 inhibition have been observed in
diverse models and the efficacy achieved has been most consistent [11, 33]. This specificity fur-
ther strengthens and validates the therapetutic rationale and provides a mechanistic basis for
clinical development of brain-penetrant SIRT2 inhibitors as candidate neuroprotectants for
PD, HD, and possibly other related neurodegenerative diseases.
Materials and Methods
Biochemical characterization of SIRT2 inhibition property of AK7
SIRT2 protein preparation and deacetylation assays. The human SIRT2 catalytic domain (res-
idues 43–356) was cloned into pET-SUMO using Nde1 and Xho1. SIRT2 was expressed using
autoinduction in E. coli Codon+ as previously described [22]. Harvested cells were resuspended in
50 mM Tris pH 8.0, 500 mMNaCl, 5% glycerol, disrupted using an EmulsiFlex C3 homogenizer
(Avestin) and cell debris removed by 45 min centrifugation at 4°C and 20,000 rpm in a HFA22.50
rotor. An affinity chromatography was performed using a HisTrap column (GEHealthcare) and
SIRT2 eluted with buffer supplemented with 250 mM imidazol. The fusion protein was digested
overnight at 4°C using Sumo-protease and subjected to a reverse affinity purification step. SIRT2
was finally ran over a Superdex 200 gel filtration column (GE healthcare) in 20 mMTris pH 8.0,
150 mMNaCl, 1 mM TCEP, analyzed by SDS –PAGE, concentrated, and kept at 4°C.
Deacetylase activity assays were performed as described [34]. Briefly, the reaction mix con-
tained 0.8 μM Sirt2 (43–356), 200 μM or 1 mMNAD+ and 80 or 400 μM α-tubulin peptide,
MPSD(ac)KTIG (GL Biochem) and AK7 concentrations from 0 to 64 μMwith constant 5%
DMSO in a 20 mMNa-phosphate buffer at pH 7.5. The reaction was started by adding human
recombinant SIRT2 and followed for 45min at 340 nm in a MQX200 (MWG-Biotech) micro-
plate reader. The background signal was measured under similar conditions omitting the sub-
strate peptide from the reaction. Results are the average of at least four measurements and IC50
values were determined using Grafit 7 (Erathicus Software).
Docking of AK7 to the SIRT2 active site. For generating SIRT2/AK7 models, the com-
pound was docked using the program FlexX (BioSolveIT) and different SIRT2 conformations:
The SIRT2 complex with ADP-ribose (pdb ID 3zgv; ligand omitted for the calculation) [22]
(Fig. 1B), the SIRT2 complex with a macrocyclic inhibitor peptide (4l3o) [35] (S1A Fig.), or a
model of an acetyl-lysine bound SIRT2 generated using 3zgv for the protein and the macrocy-
clic peptide from 4l3o for the acetyl lysine (S1B Fig.). In all cases the best pose was visualized in
the receptor using PyMol (Schrödinger LLC).
Drug-treatment in viability assay in differentiated LUHMES cells
overexpressing aSyn
LUHMES cells, which were a kind gift from Dr. Marcel Leist, University of Konstanz, Germany
[23] were maintained as proliferating cultures and differentiated into post-mitotic neuron-like
Table 1. Effects of AK7 in a mouse model of ischemic stoke.
Vehicle (n = 9) AK7 (n = 10) p
Mortality (mice) 1/9 2/10 >0.05
infarct volumes (mm3) 76 ± 26 85 ± 28 >0.05
ischemic tissue swelling (mm3) 6 ± 8 9 ± 8 >0.05
neurological deficit scores (median [interquartile range] 2.0 [1.0–2.3] 1.5 [1.0–2.0] >0.05
doi:10.1371/journal.pone.0116919.t001
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cells on Nunclon plates and flasks, pre-coated with 50 g/mL poly-L-ornithine (Sigma) and
1 g/mL fibronectin (Sigma), as previously described [23, 24]. Briefly, 8×106 proliferating
cells were seeded into a T175 flask containing proliferation medium, consisting of advanced
DEMEM/F12 (Invitrogen), 2 mM L-glutamine (Sigma-Aldrich), 1× N2 supplement (Invitrogen)
and 40 ng/mL recombinant human bFGF (R&D Systems). After 24 hours, proliferation medium
was replaced with differentiation medium, composed of advanced DMEM/F12 (Invitrogen),
2 mM L-glutamine (Sigma-Aldrich), 1× N2 supplement (Invitrogen), 1 mM dibutyryl 3’, 5’-cyclic
adenosine monophosphate (Sigma-Aldrich), 2.25 M tetracycline and 2 ng/mL recombinant
human GDNF (R&D Systems). 48 hr later, cells were trypsinized and seeded into 24-well plates,
containing 1mL of differentiation medium and 250,000 cells/well.
Lenti-virus based expression of aSyn transfer plasmids. Full-length human aSyn cDNA
was subcloned into a second-generation of lentiviral vector pWPI (Tronolab, Switzerland), fol-
lowed by an IRES-EGFP sequence. The original promoter (EF1) was replaced by the chicken/
β-actin promoter. The vector including only the IRES-GFP cassette was used for control exper-
iments. The correct nature of all cloned sequences was confirmed by automated sequencing
(StarSeq, Mainz Germany). For lentiviral shRNA production a third generation lentiviral vec-
tor pLKO.1 puro (from Sigma Aldrich) containing the following sequence 5’-ACCAAAGAGC
AAGTGACAAAT-3’ was used to knock down the gene expression for human SNCA. Control
experiments were performed with the vector pLKO.1 puro containing the scrambled sequence
5’-CCTAAGGTTAAGTCGCCCTCG-3’. Second-generation lentiviral particles were generated
as described previously [37]. After purification of the modified transfer-vectors and cotransfec-
tion with the packaging vectors (Tronolab, Switzerland) into LUHMES cells (Invitrogen) for
48 hr, the supernatant was collected, concentrated by PEG-it Virus Precipitation Solution
(System Biosciences) and resuspended in Panserin 401 (PAN, Germany). The measurement of
transgene expression has been determined by qRT PCR using SYBR GREEN, and specific
primers to the woodchuck hepatitis virus post transcriptional regulatory element (WPRE) as
described previously [36]. Viruses were used equimolarly in all applications, stored at −80°C,
and kept on ice during cell culture procedures. Transduction was accomplished by incubating
undifferentiated LUHMES cells with virus-containing supernatant for 48 hr. GFP-positive cells
were selected via FACS sorting (BD Aria II). Viruses were used equimolarly in all applications,
stored at −80°C, and kept on ice during cell culture procedures.
Cell viability assay. Cell viability was measured by cellular release of adenylate kinase (AK)
using quantitative bioluminescent cytotoxicity assay (ToxiLight BioAssay (Lonza) according to
the manufacturer’s protocol. 72 hr after cells were seeded into 24-well plates, 500 L of condi-
tioned supernatants were replaced with fresh differentiation medium, containing each of the
compounds or vehicle control (DMSO). 96 hr after that, 20 L of cell culture supernatants were
added to individual wells of a black-walled, clear-bottom, 96-well microtiter plate. Next, 100 L
of ToxiLight AK reagent was added to each well and incubated at room temperature for 5 min.
Luminescence was measured, using an Infinte M200 PRO (Tecan) plate reader, and lumines-
cence results of the test wells were expressed as percentage of the control wells.
Drug trial MPTPmouse model of PD
Animals and treatment regimens.Male C57BL/6 mice (* 25 g) from the Jackson Laborato-
ries were housed in temperature- and humidity- controlled rooms with a 12-hr dark: light
cycle and had free access to food and water. In an acute intoxication paradigm, AK7 was ad-
ministered i.p. 10min before and 50 min after a single dose of 40 mg/kg MPTP-HCl i.p. In sub-
acute toxin model, mice were injected with 20 mg/kg MPTP-HCl i.p. once daily for 4 days,
AK7 was administered i.p. at indicated doses 10 min before and 50 min after each MPTP
Neuroprotective Effects of the SIRT Inhibitor AK-7
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injection. Control animals received vehicle (25% cremophor in PBS) injection. The injection
times were determined based on metabolism of both AK7 and MPTP in mouse brain [13, 25].
Beam test. For mice that were treated with subacute MPTP regimen, three days after the last
MPTP injection, animals were placed on an increasingly narrower beam and total number of
steps and time to traverse were recorded. All animals were trained before treatment started [37].
Measurement of DA and metabolite.Mice were sacrificed 7 days after a single dose of
MPTP in acute regimen and 5 days after the last MPTP injection in subacute regimen by rapid
cervical dislocation, and their striata were dissected. DA and its metabolite DOPAC were deter-
mined HPLC coupled with ECD [38].
TH immunohistochemistry and stereological quantification. Dopaminergic neuron
marker TH immunostaining was performed using mouse anti-TH antibody (Sigma, ST. Louis,
MO) at 1:1000. Total numbers of TH positive neurons in the SN were counted under blinded
conditions using the Bioquant Image Analysis System (R&M Biometrics, Nashville, TN) [38].
Western blot. To detect Ac α-tubulin, α-tubulin, and SIRT2.2 in the striatum, mice were
treated with subchornic MPTP regimen and were sacrifice 24 hr after the last MPTP injection.
Fresh frozen striatal tissue samples were homogenized and proteins were extracted as previous-
ly described [5]. Immunoblotting was performed using the following primary antibodies: rabbit
anti-SIRT2 (S8447, Sigma-Aldrich), mouse anti-GAPDH (clone 6C5, MAB374, Millipore),
mouse anti-α-tubulin (T6074, Sigma-Aldrich), mouse anti-acetylated α-tubulin (clone 611B-1,
T6793, Sigma-Aldrich), and rabbit anti-actin (A2066, Sigma-Aldrich). Secondary antibodies
were horseradish peroxidase-conjugated anti-rabbit or anti-mouse IgG (Sigma-Aldrich). Band
intensity was quantified using ImageJ [5].
Drug trial in the mutant SOD1-G93A mouse model of ALS
Transgenic ALS model mice used in this study carry the human G93A mutant allele of SOD1
[26] on the C57BL/6 background [39]. SOD1-G93A mice on the C57BL/6 background exhibit
delayed onset of clinical symptoms and extended lifespan as compared to the commonly used
B6SJL hybrid strain [40], although the overall duration of disease is unchanged. Study animals
were generated by backcrossing male B6.Cg-Tg (SOD1G93A)1Gur/J mice (obtained from
The Jackson Laboratory, Bar Harbor, ME) to C57BL/6J females. Mice were genotyped by PCR
of tail-tip DNA and housed under standard conditions with free access to food and water.
For drug studies, SOD1-G93A transgenic animals from the same backcross generation were
randomly assigned to treatment groups at 55 days of age. Both males are females were used,
and sexes and littermates were balanced across treatment groups. AK7 (20 mg/kg) or vehicle
(5% Cremaphor in PBS) was administered daily via i.p. injection beginning at 60 days of age,
before time of disease onset, which is 120 days of age. Mice were weighed and assessed twice
weekly for the first signs of disease onset using a standard neurological scoring system for ALS
mice. Onset of symptoms was determined by the first appearance of neurological deficit, de-
fined as the inability of the animal to fully splay its hindlimbs when briefly held suspended by
its tail. Survival is defined as age at death or euthanasia due to end-stage disease. An animal at
end-stage disease is euthanized when it cannot 1) right itself within 15 seconds of being placed
on its side, 2) groom its face (detected by the development of infections in one or both eyes), or
3) move around to reach food placed on the cage floor. Time of disease onset and survival were
compared among treatment groups using Kaplan-Meier curves and the Log-Rank test.
Drug trial in an experimental mouse model of cerebral ischemia
Wild type mice (8–10 week-old male C57B6/J; Charles River Labs) were treated with AK7
(30 mg/kg i.p., diluted in 5% cremophor in PBS) or vehicle once at reperfusion (post-ischemic
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cohort). In a separate cohort, mice were treated twice a day for two days before stroke
induction, and then received a dose immediately before the stroke and an additional dose in
the evening (peri-ischemic cohort). Because outcomes did not vary between post-ischemic and
peri-ischemic treatment paradigms, the data were pooled. Mice were anesthetized by isoflurane
(3% induction, 2% maintenance in 30% O2, 70% N2O), and rectal temperature maintained be-
tween 36–36.5°C (FHC, ME, USA). Cerebral blood flow was continuously monitored over the
parietal cortex by laser Doppler during the entire procedure. After midline incision, the right
carotid artery bifurcation was dissected and external carotid ligated. A clip was then placed on
the internal carotid artery, common carotid temporarily ligated. A commercial silicon coated
filament (7019, Doccol Corp, MA, USA) was then inserted through the external into the inter-
nal carotid artery, and advanced to the middle cerebral artery origin, occlusion of which was
confirmed by cerebral blood flow reduction to less than 20% of baseline. The filament was
gently pulled out after 1 hour and common carotid ligation released. Successful reperfusion
was confirmed by restoration of cerebral blood flow. Mice were placed in a temperature-
controlled incubator with easy access to food and water, and body weight was monitored.
Neurological outcomes were scored 24 hr after stroke using the following grading system:
no neurological deficit (0), forepaw extension deficit during clasping reflex (1), circling
behavior (2), comatose (3) and death (4). Mice were euthanized 24 hr after stroke onset with a
lethal dose of isoflurane followed by decapitation. Infarct volume was assessed in a blinded
fashion by integrating the infarct area in ten 1-mm-thick coronal sections soaked in 2% 2,3,5-
triphenyltetrazolium chloride (Sigma, St. Louise, MO) for 15 min protected from light. Infarct
volume was calculated by subtracting the volume of ipsilateral non-infarcted tissue from the
contralateral hemisphere. Ischemic swelling volume was calculated by subtracting the volume
of contralateral hemisphere from the volume of ipsilateral hemisphere.
Ethics statements
The animal experiments were carried out in strict accordance with the recommendations in
the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Massachusetts General Hospital Animal Care and Use Commit-
tee (approval number 2006N000120) or co-authors’ institutions. Animals were sacrificed by
rapid cervical dislocation or euthanized by isoflurane. All efforts were made to
minimize suffering.
Statistical analysis
All values are expressed as mean ± SEM. The difference between two groups was analyzed by
the t test. Multiple comparisons among groups were performed by one-way analysis of variance
and Tukey post hoc analyses. p<0.05 was considered statistically significant.
Supporting Information
S1 Fig. Docking models of a SIRT2/AK7 complex. The structure of SIRT2 (PDB ID 3zgv) is
shown in gold with the catalytic His187. ADP-ribose (3zgv) and substrate acetylated lysine are
shown in light green and deep teal, respectively. AK7 was docked either to Sirt2 in complex
with a macrocyclic inhibitor peptide (PDB ID 4l3o) (1A) or to a model of an acetyl-lysine
bound SIRT2 generated using 3zgv for the protein and the macrocyclic peptide from 4l3o for
the acetyl lysine model (1B). In each cases, the best pose of AK7 (magenta) mainly occupies the
NAD+ binding site. (C, D) Protective effects against aSyn toxicity in LUHMES cells of novel
SIRT2 inhibitor MIND4-11. MIND4-11 has been identified as selective SIRT2 inhibitor of im-
proved potency (IC50~5mM), albeit lacking brain-permeable property. (C) LUHMES cells
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were transduced with a lentivirus encoding aSyn. 10 days after differentiation, in the presence
of vehicle alone (red, 100% toxicity) or different concentrations of MIND4-11 (black line),
media were collected and AK activity was measured. (D) Percentage of AK activity in the pres-
ence of 12.5 M of MIND4-11, compared to vehicle-treated cells ( p< 0.001).
(TIF)
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